Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.
about
Individualized survival and treatment response predictions in breast cancer patients: involvements of phospho-EGFR and phospho-Her2/neu proteinsTrastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancerFunctional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.Molecular Mechanisms and Translational Therapies for Human Epidermal Receptor 2 Positive Breast CancerComparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment methodµFBI: a microfluidic bead-based immunoassay for multiplexed detection of proteins from a µL sample volumePhosphorylation state-specific antibodies: applications in investigative and diagnostic pathology.Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab.MicroRNA and HER2-overexpressing cancer.Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer.MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistanceCooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells.The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-β Signaling in Breast Cancer Malignancy.Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of actionPrognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancerPhosphatidylinositol-3-kinase as a therapeutic target in melanomaTargeted therapy in breast cancer: the HER-2/neu gene and protein.When tumor suppressor TGFβ meets the HER2 (ERBB2) oncogene.Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapyEstrogen receptor, progesterone receptor, and Her 2 Neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan.Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment.Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteinsCirculating long non-coding HOX transcript antisense intergenic ribonucleic acid in plasma as a potential biomarker for diagnosis of breast cancer.Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients.A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity.Bringing cancer serological diagnosis to a new level: focusing on HER2, protein ectodomain shedding and neoepitope technology.Evaluation of HER2 in breast cancer: reality and expectations.Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin.Combinatorial treatment of mammospheres with trastuzumab and salinomycin efficiently targets HER2-positive cancer cells and cancer stem cells.The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer.Zinc finger transcription factors designed for bispecific coregulation of ErbB2 and ErbB3 receptors: insights into ErbB receptor biology.Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance.relocating job wise? A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor.
P2860
Q23916643-779F1AE8-4683-4977-BCD4-20E2C4E7693DQ24795614-5F456D7B-9504-4E9E-876D-0D93F5273FE1Q24813543-BE23E066-57C6-475C-BF2F-F99CA5DA1A84Q28072513-AD7669AE-73F9-47A9-AA8E-4595B4FC60D5Q28535362-AA18269A-BC74-4C57-933B-B246C6A4D3BCQ28749053-C8EEC0BB-7604-40DD-8649-F23119BFA4EEQ30311912-137A5312-B0CE-4F76-82EF-B7062A5C2243Q33284158-0D5BFE5E-72E9-404D-9670-F2EBA201B135Q33680890-0131AD4B-6516-484D-88DB-7B4A48734B6EQ33994744-B9DAF8E1-A674-4A5F-9DE0-20065CC61417Q34436356-B3AF670A-D0BB-4682-8455-7AA4604C0775Q34506613-4994CEC1-3023-4358-A72F-3E515E748B59Q34713799-EE976533-FB27-4030-AD34-11D2FF8D2303Q34756694-472389F3-79A6-4E12-A3E3-11196435072AQ34769657-C8110156-15A6-47AC-9095-7AB20F028B44Q35005626-7D6188D7-8989-4ADC-A04B-E760EF7466FAQ35559032-E112AC5C-7960-4BEB-A8EA-1A712FAB803CQ35584641-DDE656D5-9EF8-4DA3-86F3-8F44E020578CQ35606261-42F9ACB7-4BFF-47EB-9665-7A3C9B4E08AEQ35648508-753ED663-4120-4489-9124-D216D029964CQ36098453-44C0D3A6-75ED-40B0-8600-3C88EFC20C8DQ36223407-B96A5EF7-BF66-4CCF-AEDC-2E3C0D5A16E7Q36489321-8A02AB30-22BE-4022-84D7-B45C09A41641Q36648369-39277738-08C8-480F-9BBE-C08D28D08E38Q37163481-2F441222-CC92-4659-B8F3-716FAE1BC1DBQ37205574-E3747BB1-BB92-401C-9F71-28A63B8CDF26Q37355431-7E7F4B34-9223-40BB-B3C6-B2063B9A3785Q37389593-B1477DC3-BF40-4FF0-A705-D551238F3E88Q37413628-8D6C7B3A-DB34-4F66-A7A0-A6126EF816BFQ37694673-68757BA9-D743-45C7-9F0C-1824F882FBF2Q38068491-1252DA54-767F-438D-8DD6-E815E81E061EQ38089837-A67F1C60-25BA-4073-96E4-0C3B71AA0DBEQ38440660-07151DD7-C728-4FE6-88CB-093719BDF482Q38710973-FD2ECB30-8B3A-4086-8512-C98D694651ECQ39363067-24A9225F-E28B-4986-82A7-95267F261F17Q39406282-CDEED18B-5301-46D5-BEC8-53FFD5ED5513Q39986043-CF47627A-44C7-401A-8925-C6C24A5595D0Q40366552-B5718F5A-98E6-4F35-8553-AE75E0A50348Q40718678-ABD23463-9C2B-4806-835B-330CB6671063Q42851885-DE374687-05B5-43B1-8764-C896B80FC0B4
P2860
Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Activation (tyrosine phosphory ...... with outcome in breast cancer.
@en
type
label
Activation (tyrosine phosphory ...... with outcome in breast cancer.
@en
prefLabel
Activation (tyrosine phosphory ...... with outcome in breast cancer.
@en
P2093
P1476
Activation (tyrosine phosphory ...... with outcome in breast cancer.
@en
P2093
K M Kasowitz
M P DiGiovanna
S Edgerton
P304
P356
10.1200/JCO.2000.18.18.3230
P407
P577
2000-09-01T00:00:00Z